Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L‑4‑Chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (MDD)

Trial Profile

Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L‑4‑Chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (MDD)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs AV 101 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors VistaGen Therapeutics
  • Most Recent Events

    • 26 Oct 2017 According to a VistaGen Therapeutics media release, the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed , under its Investigational New Drug (IND) application, with this trial. The trial is expected to begin in the first quarter of 2018
    • 03 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
    • 03 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top